About the Lab
Our Lab is situated at the first floor of the UCY Medical School building (the Siakolas Educational Centre for Clinical Medicine), Lab Room 101. The Lab was built in 2016 as part of a major building refurbishment that started a year earlier, in order to house the Medical School of the University of Cyprus. Meet the Lab's members here.
The Lab's mission is:
The Lab's Research and Objective
Our research revolves around novel drug discovery and drug repurposing screenings in vitro & in vivo. We focus on the exploration of the pharmacological characterization of drugs on selected molecular targets and organism behaviour in zebrafish. We apply this knowledge in order to discover new drugs or find new therapeutic applications of existing clinical drugs, against a number of chronic diseases, such as neuropathic pain, cancer, neurodegenerative diseases and chronic infections. We work towards this aim by applying customized screening projects of library drug sets on developed drug-target assays for hit selection and lead identification.
Check our Lab's progress through our Lab News page.
Our Lab is situated at the first floor of the UCY Medical School building (the Siakolas Educational Centre for Clinical Medicine), Lab Room 101. The Lab was built in 2016 as part of a major building refurbishment that started a year earlier, in order to house the Medical School of the University of Cyprus. Meet the Lab's members here.
The Lab's mission is:
- To lead the Medical School's laboratory research in drug discovery and develop research activities that will translate into therapeutic applications.
- To provide quality research training in preclinical and clinical pharmacology for medical students and support the School's postgraduate research programs in the area of drug science and experimental therapeutics.
The Lab's Research and Objective
Our research revolves around novel drug discovery and drug repurposing screenings in vitro & in vivo. We focus on the exploration of the pharmacological characterization of drugs on selected molecular targets and organism behaviour in zebrafish. We apply this knowledge in order to discover new drugs or find new therapeutic applications of existing clinical drugs, against a number of chronic diseases, such as neuropathic pain, cancer, neurodegenerative diseases and chronic infections. We work towards this aim by applying customized screening projects of library drug sets on developed drug-target assays for hit selection and lead identification.
Check our Lab's progress through our Lab News page.
The Lab's Research Portfolio
To achieve our objectives we combine the key capacity & equipment of our Lab (such as our drug library, HTS capacity and zebrafish modelling) with specialised expertise in various pharmacological assays using molecular and behavioural modelling. Explore our Lab's research portfolio and current projects.
To achieve our objectives we combine the key capacity & equipment of our Lab (such as our drug library, HTS capacity and zebrafish modelling) with specialised expertise in various pharmacological assays using molecular and behavioural modelling. Explore our Lab's research portfolio and current projects.
The Lab's vision
The Lab aspires to play an important role in bridging pre-clinical and clinical studies in Cyprus through target-based and disease-orientated high-throughput screening of novel and clinical drugs on various models of disease. Our vision is to become a national centre of research excellence in drug discovery and translational pharmacological studies.
Alignment with the Strategic Aims of the Republic of Cyprus
The Lab is fully aligned with the Republic of Cyprus Smart Specialization Strategy (S3Cy) of the Directorate General for European Programmes, Coordination and Development. More specifically, the Lab falls under the Health Section of the S3Cy and its aims and activities align fully with Priority C: "Development of Safe & Effective Drugs", in particularly Priority C3: "Molecular Diagnostics and Production of Specialized Drugs" which is characterised by the Republic as 'High Priority'. You can find out more about the S3Cy here.
The Lab aspires to play an important role in bridging pre-clinical and clinical studies in Cyprus through target-based and disease-orientated high-throughput screening of novel and clinical drugs on various models of disease. Our vision is to become a national centre of research excellence in drug discovery and translational pharmacological studies.
Alignment with the Strategic Aims of the Republic of Cyprus
The Lab is fully aligned with the Republic of Cyprus Smart Specialization Strategy (S3Cy) of the Directorate General for European Programmes, Coordination and Development. More specifically, the Lab falls under the Health Section of the S3Cy and its aims and activities align fully with Priority C: "Development of Safe & Effective Drugs", in particularly Priority C3: "Molecular Diagnostics and Production of Specialized Drugs" which is characterised by the Republic as 'High Priority'. You can find out more about the S3Cy here.